Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04841148). This is a study registration, not published results. Lead sponsor: Abramson Cancer Center at Penn Medicine. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 96 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DRUG: HCQ; DRUG: Avelumab; DRUG: Palbociclib. Primary outcome measures: Determine the efficacy of HCQ or Avelumab, alone or in combination with Palbociclib, in eradicating DTCs , Efficacy is assessed at the end of Cycle 6 (each cycle is 28 days).. Brief summary: This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.